NASDAQ · OCS
Healthcare · Biotechnology
$10.07
Down-$0.53 (-5.00%)
Updated Sep 16, 2026, 8:19 AM
SID Score
2.6/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
OCS closed at $10.07 after 20 trading sessions, down 23.65% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $10.60 | $10.61 | $10.00 | $10.07 | 159.31K |
| Sep 14, 2026 | $10.56 | $10.835 | $10.51 | $10.60 | 153.19K |
| Sep 11, 2026 | $11.39 | $11.98 | $10.50 | $10.56 | 226.62K |
| Sep 10, 2026 | $11.34 | $11.60 | $11.00 | $11.31 | 169.33K |
| Sep 9, 2026 | $12.11 | $12.13 | $11.40 | $11.47 | 164.46K |
| Sep 8, 2026 | $12.085 | $12.24 | $11.93 | $12.16 | 138.63K |
| Sep 4, 2026 | $12.07 | $12.66 | $11.93 | $12.17 | 124.35K |
| Sep 3, 2026 | $12.10 | $12.29 | $11.96 | $12.17 | 179.23K |
| Sep 2, 2026 | $12.20 | $12.395 | $11.95 | $12.02 | 183.09K |
| Sep 1, 2026 | $12.17 | $12.29 | $12.02 | $12.18 | 83.36K |
| Aug 31, 2026 | $12.11 | $12.335 | $11.99 | $12.25 | 114.05K |
| Aug 28, 2026 | $12.38 | $12.50 | $12.14 | $12.21 | 221.87K |
| Aug 27, 2026 | $12.88 | $13.115 | $12.42 | $12.43 | 111.45K |
| Aug 26, 2026 | $12.98 | $13.06 | $12.81 | $12.97 | 161.92K |
| Aug 25, 2026 | $13.25 | $13.42 | $12.90 | $12.96 | 192.37K |
| Aug 24, 2026 | $13.10 | $13.25 | $12.87 | $13.18 | 150.39K |
| Aug 21, 2026 | $13.17 | $13.2746 | $13.00 | $13.085 | 76.46K |
| Aug 20, 2026 | $13.41 | $13.54 | $13.04 | $13.14 | 111.22K |
| Aug 19, 2026 | $13.21 | $13.70 | $13.15 | $13.57 | 272.42K |
| Aug 18, 2026 | $13.07 | $13.20 | $12.8893 | $13.19 | 198.87K |
The latest Smart Investors Daily articles mentioning OCS.
OCS research
Company profile and research snapshot.
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 14, 2026 | JP Morgan | Overweight | — |
| Aug 5, 2026 | HC Wainwright & Co. | Buy | — |
| Jun 3, 2026 | JP Morgan | Overweight | — |
| Jun 2, 2026 | Baird | Outperform | — |
| Jun 1, 2026 | Stifel | Buy | — |
No generated briefing is available yet.
Yahoo · Aug 31, 2026
The mean of analysts' price targets for Oculis Holding AG (OCS) points to a 199.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Benzinga · Aug 14, 2026
JP Morgan analyst Tessa Romero maintains Oculis Holding (NASDAQ:OCS) with a Overweight and lowers the price target from $23 to $20.
Yahoo · Aug 10, 2026
Oculis Holding (OCS) has agreed to acquire all of Accure Therapeutics' worldwide development and com
Yahoo · Aug 10, 2026
Transaction will enhance Oculis’ strategic flexibility and ownership of Privosegtor while driving long-term value creationTransaction consideration includes $3.8 million up-front cash payment at closing and up to 2,050,000 Oculis ordinary shares subject to lockup release over a period of up to 2 years, or vesting upon achievement of development and regulatory milestonesPrivosegtor, a neuroprotective drug candidate, is currently being investigated in registrational trials with initial indications
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning OCS.
